Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H28N2O5 |
Molecular Weight | 376.4467 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(=O)N(C1=CC=CC=C1)C2(CCN(CCC(=O)OC)CC2)C(=O)OC
InChI
InChIKey=ZTVQQQVZCWLTDF-UHFFFAOYSA-N
InChI=1S/C20H28N2O5/c1-4-17(23)22(16-8-6-5-7-9-16)20(19(25)27-3)11-14-21(15-12-20)13-10-18(24)26-2/h5-9H,4,10-15H2,1-3H3
Molecular Formula | C20H28N2O5 |
Molecular Weight | 376.4467 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. ULTIVA is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The
µ-opioid activity of ULTIVA is antagonized by opioid antagonists such as naloxone. ULTIVA is indicated for IV administration:
1. As an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures.
2. For continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting.
3. As an analgesic component of monitored anesthesia care in adult patients.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ULTIVA Approved UseULTIVA is indicated for IV administration: 1.As an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. 2.For continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting. 3.As an analgesic component of monitored anesthesia care in adult patients. Launch Date8.371296E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
194 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL ACID blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
14 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8080 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL ACID blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
745 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.48 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL ACID blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11.4 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
30% |
0.5 μg/kg/min 1 times / day other, intravenous dose: 0.5 μg/kg/min route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
[Total intravenous anesthesia (TIVA) and balanced anesthesia with short-acting anesthetics for ENT surgery in children]. | 1999 |
|
Remifentanil, propofol or both for conscious sedation during eye surgery under regional anaesthesia. | 1999 Nov |
|
Bradycardia after administration of remifentanil. | 2000 Mar |
|
Anesthesia for magnetic resonance guided neurosurgery: initial experience with a new open magnetic resonance imaging system. | 2001 Apr |
|
Remifentanil. | 2001 Aug |
|
Target-controlled infusion or manually controlled infusion of propofol in high-risk patients with severely reduced left ventricular function. | 2001 Aug |
|
Small doses of remifentanil or sufentanil for blunting cardiovascular changes induced by tracheal intubation: a double-blind comparison. | 2001 Feb |
|
Influence of hemorrhagic shock on remifentanil: a pharmacokinetic and pharmacodynamic analysis. | 2001 Feb |
|
Sevoflurane--nitrous oxide anaesthesia supplemented with remifentanil: effect on recovery and cognitive function. | 2001 Feb |
|
The effect of remifentanil on the heat pain threshold in volunteers. | 2001 Feb |
|
Use of remifentanil in a patient with peripartum cardiomyopathy requiring Caesarean section. | 2001 Jan |
|
Remifentanil versus meperidine for monitored anesthesia care: a comparison study in older patients undergoing ambulatory colonoscopy. | 2001 Jan |
|
Opioid chronopharmacology. | 2001 Jul |
|
Esmolol is not an alternative to remifentanil for fast-track outpatient gynecologic laparoscopic surgery. | 2001 Jul |
|
Monitored anesthesia care using remifentanil and propofol for awake craniotomy. | 2001 Jul |
|
Sevoflurane with remifentanil allows rapid tracheal intubation without neuromuscular blocking agents. | 2001 Jul-Aug |
|
Recovery after remifentanil and sufentanil for analgesia and sedation of mechanically ventilated patients after trauma or major surgery. | 2001 Jun |
|
Safety and efficacy of remifentanil infusion in craniosynostosis repair in infants. | 2001 Jun |
|
Remifentanil- and fentanyl-based anesthesia for intraoperative monitoring of somatosensory evoked potentials. | 2001 Jun |
|
Recovery from propofol anaesthesia supplemented with remifentanil. | 2001 Mar |
|
[Alterations in left ventricular-arterial coupling and mechanical efficiency produced by remifentanil during cardiac anesthesia]. | 2001 Mar |
|
Intravenous anaesthesia with remifentanil in a preterm infant. | 2001 Mar |
|
[Esterase-metabolized remifentanil hydrochloride opioid (Ultiva-TM), a new step towards the solution of the problem of regulation of analgetic components of general anesthesia]. | 2001 Mar-Apr |
|
[Anesthesia in extreme obesity]. | 2001 May |
|
Dose-dependent regional cerebral blood flow changes during remifentanil infusion in humans: a positron emission tomography study. | 2001 May |
|
A patient with hypertrophic obstructive cardiomyopathy presenting for total knee replacement. | 2001 May |
|
Propofol and remifentanil pharmacodynamic interaction during orthopedic surgical procedures as measured by effects on bispectral index. | 2001 May |
|
Effect of age on recovery from remifentanil anaesthesia. | 2001 Oct |
|
Threshold-level repetitive transcranial electrical stimulation for intraoperative monitoring of central motor conduction. | 2001 Oct |
|
Does functional ability in the postoperative period differ between remifentanil- and fentanyl-based anesthesia? | 2001 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/remifentanil.html
Usual Adult Dose for Anesthesia
Induction of Anesthesia: Continuous IV infusion: 0.5 to 1 mcg/kg/min. If endotracheal intubation is to occur in less than 8 minutes, an initial dose of 1 mcg/kg may be administered over 30 to 60 seconds.
Maintenance of Anesthesia: With Nitrous Oxide, 0.4 mg/kg/min by continuous IV infusion.
Infusion dose range: 0.1 to 2 mcg/kg/min.
Supplemental IV bolus: 1 mcg/kg every 2 to 5 minutes.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16507200
Remifentanil (10(-8) - 10(-4) mol/ L) caused a concentration-dependent vasorelaxation in the human being artery rings.
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 22:37:49 UTC 2023
by
admin
on
Thu Jul 06 22:37:49 UTC 2023
|
Record UNII |
P10582JYYK
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67413
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
||
|
WHO-VATC |
QN01AH06
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
||
|
WIKIPEDIA |
List_of_fentanyl_analogues
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
||
|
NDF-RT |
N0000175690
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
||
|
WHO-ATC |
N01AH06
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
||
|
DEA NO. |
9739
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
||
|
NDF-RT |
N0000175684
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
||
|
NCI_THESAURUS |
C1506
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C66513
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
P10582JYYK
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
DB00899
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
CHEMBL1005
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
M9521
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | Merck Index | ||
|
2363
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
Remifentanil
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
132875-61-7
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
REMIFENTANIL
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
SUB10272MIG
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
8802
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
7292
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
C071741
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
6924
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
73032
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | RxNorm | ||
|
REMIFENTANIL
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. Remifentanil is used as an opioid analgesic that has a rapid onset and rapid recovery time. It has been used effectively during craniotomies, spinal surgery, cardiac surgery, and gastric bypass surgery. While opiates function similarly, with respect to analgesia, the pharmacokinetics of remifentanil allows for quicker post-operative recovery. | ||
|
100000089165
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
DTXSID00157826
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
60815
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY | |||
|
P10582JYYK
Created by
admin on Thu Jul 06 22:37:50 UTC 2023 , Edited by admin on Thu Jul 06 22:37:50 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
Potency higher than fentanyl (IC50=1.23 NM) fast onset and short duration of action.
IC50
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
MINOR
|
||
|
METABOLITE -> PARENT |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|